NUS
Nu Skin Enterprises, Inc. NYSE$7.05
After hrs
$7.33
-0.00%
Mkt Cap $346.7M
52w Low $5.63
15.8% of range
52w High $14.62
50d MA $7.56
200d MA $9.77
P/E (TTM)
2.2x
EV/EBITDA
4.2x
P/B
0.4x
Debt/Equity
0.5x
ROE
19.9%
P/FCF
10.3x
RSI (14)
—
ATR (14)
—
Beta
1.07
50d MA
$7.56
200d MA
$9.77
Avg Volume
518.7K
About
Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplem…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | AMC | 0.30 | 0.29 | -3.3% | 10.21 | -15.1% | -18.1% | -15.7% | -16.7% | -15.2% | -14.7% | — |
| Nov 6, 2025 | AMC | 0.30 | 0.34 | +13.3% | 10.83 | -4.0% | -15.8% | -8.9% | -11.6% | -11.4% | -9.7% | — |
| Aug 7, 2025 | AMC | 0.25 | 0.43 | +72.0% | 8.20 | +3.9% | +8.9% | +29.0% | +36.0% | +40.7% | +39.5% | — |
| May 8, 2025 | AMC | 0.15 | 0.23 | +53.3% | 6.16 | +7.1% | +11.0% | +20.8% | +20.6% | +18.8% | +21.3% | — |
| Feb 13, 2025 | AMC | 0.24 | 0.38 | +58.3% | 6.42 | +38.3% | +17.8% | +13.2% | +22.0% | +20.4% | +18.4% | — |
| Nov 7, 2024 | AMC | 0.20 | 0.17 | -15.0% | 6.45 | -0.8% | +1.6% | +11.9% | +12.1% | +16.0% | +11.5% | — |
| Aug 8, 2024 | AMC | 0.18 | 0.21 | +16.7% | 10.40 | +3.0% | -3.2% | -13.0% | -9.1% | -7.7% | -5.1% | — |
| May 8, 2024 | AMC | 0.05 | 0.09 | +80.0% | 12.42 | +1.9% | +2.9% | +6.4% | +8.8% | +11.8% | +9.4% | — |
| Feb 14, 2024 | AMC | 0.29 | 0.37 | +27.6% | 17.43 | -23.3% | -20.7% | -21.5% | -25.2% | -27.4% | -29.5% | — |
| Nov 1, 2023 | AMC | 0.64 | 0.56 | -12.5% | 18.62 | -6.7% | -9.5% | -3.4% | -6.8% | -7.5% | -12.0% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 20 | DA Davidson | Maintains | Neutral → Neutral | — | $6.87 | $6.69 | -2.6% | -3.9% | -2.0% | -3.1% | -1.0% | -1.6% |
| Oct 22 | Citigroup | Maintains | Neutral → Neutral | — | $6.16 | $6.10 | -1.0% | -1.1% | +2.6% | +1.9% | +0.0% | +0.3% |
| Aug 12 | DA Davidson | Maintains | Neutral → Neutral | — | $10.07 | $9.78 | -2.9% | -10.1% | -6.2% | -4.7% | -2.0% | -2.8% |
| Aug 9 | Citigroup | Maintains | Neutral → Neutral | — | $10.40 | $10.71 | +3.0% | -3.2% | -13.0% | -9.1% | -7.7% | -5.1% |
| May 9 | DA Davidson | Maintains | Neutral → Neutral | — | $12.42 | $12.65 | +1.9% | +2.9% | +6.4% | +8.8% | +11.8% | +9.4% |
| Jan 5 | DA Davidson | Maintains | Neutral → Neutral | — | $18.93 | $18.78 | -0.8% | -1.6% | +0.3% | -2.3% | -0.8% | -2.5% |
| Oct 16 | Stifel | Maintains | Hold → Hold | — | $18.35 | $18.62 | +1.5% | +4.4% | +6.1% | +6.9% | +7.6% | +6.3% |
| Sep 29 | Citigroup | Maintains | Neutral → Neutral | — | $21.54 | $21.56 | +0.1% | -1.5% | -3.6% | -3.9% | -5.3% | -9.7% |
| Aug 3 | DA Davidson | Maintains | Neutral → Neutral | — | $27.47 | $27.58 | +0.4% | -2.2% | -4.5% | -3.1% | -6.4% | -8.0% |
| Aug 2 | Stifel | Maintains | Hold → Hold | — | $29.74 | $29.12 | -2.1% | -7.6% | -9.7% | -11.8% | -10.5% | -13.5% |
Recent Filings
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
BAC and NUS entered new debt agreements, which could indicate either expansion financing (positive for growth) or refinancing of existing debt (neutral to negative depending on rates).
Mar 27
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
James Thomas's departure as CFO at NUS could create short-term uncertainty about financial controls and strategic direction, potentially pressuring the stock until a permanent replacement stabilizes operations.
Mar 20
8-K · 5.02
!!! Very High
NuSkin Enterprises, Inc. -- 8-K 5.02: Executive Change
NuSkin Enterprises appointed Chayce D. Clark as Executive Vice President, signaling internal leadership restructuring that investors should monitor for strategic direction changes.
Mar 9
8-K
NuSkin Enterprises, Inc. -- 8-K Filing
Nu Skin Enterprises reported fourth quarter and full-year 2025 results within guidance while forecasting a return to revenue growth by fiscal year 2026 end.
Feb 12
Data updated apr 26, 2026 4:09pm
· Source: massive.com